SVRA
Savara Inc.
$6.29
-0.09
(-1.41%)
Mkt Cap
1.29B
Volume
1,495,616
52W Range
2.24-7.005
Sector
Healthcare
Beta
0.24
EPS (TTM)
-0.56
P/E Ratio
-11.38
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 257,000 | 0 | 0 | 0 | 400,000 | 54 | 1,548 |
| Net Income | (118.84M) | (95.88M) | (54.70M) | (38.15M) | (43.01M) | (49.62M) | (78.17M) | (61.52M) | (29.80M) | (10.92M) | (39.84M) | (28.70M) |
| EPS | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 |
| Free Cash Flow | (101.06M) | (89.11M) | (51.36M) | (34.56M) | (40.14M) | (43.13M) | (45.27M) | (39.42M) | (28.73M) | (8.38M) | (33.11M) | (24.79M) |
| FCF / Share | -0.45 | -0.45 | -0.31 | -0.23 | -0.30 | -0.73 | -1.13 | -1.18 | -1.64 | -2.50 | -14.29 | -14.18 |
| Operating CF | (101.04M) | (89.09M) | (51.06M) | (34.55M) | (40.08M) | (39.84M) | (45.12M) | (39.27M) | (28.23M) | (8.37M) | (32.95M) | (24.64M) |
| Total Assets | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M | 97.75M | 136.20M | 152.29M | 159.63M | 28.93M | 54.22M | 70.50M |
| Total Debt | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M | 25.28M | 25.55M | 24.57M | 15.34M | 4.47M | 14.74M | 0 |
| Cash & Equiv | 33.18M | 15.13M | 26.59M | 52.10M | 34.01M | 22.88M | 49.80M | 24.30M | 22.12M | 13.37M | 23.05M | 35.81M |
| Book Value | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M | 64.38M | 101.70M | 108.22M | 119.31M | (35.88M) | 23.89M | 58.66M |
| Return on Equity | -0.59 | -0.56 | -0.39 | -0.35 | -0.30 | -0.77 | -0.77 | -0.57 | -0.25 | N/A | -1.67 | -0.49 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (37.28M) | (32.24M) | (29.56M) | (30.40M) | (26.64M) | (29.04M) | (24.25M) | (22.24M) | (20.35M) | (16.10M) | (16.60M) | (11.44M) |
| EPS | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.14 | -0.11 | -0.12 | -0.11 | -0.09 | -0.10 | -0.07 |
| Free Cash Flow | (33.10M) | (25.06M) | (22.53M) | (26.28M) | (27.19M) | (23.27M) | (22.67M) | (22.52M) | (20.65M) | (15.63M) | (13.20M) | (10.50M) |
| FCF / Share | -0.13 | -0.11 | -0.10 | -0.12 | -0.13 | -0.12 | -0.11 | -0.12 | -0.11 | -0.09 | -0.08 | -0.07 |
| Operating CF | (33.05M) | (25.06M) | (22.53M) | (26.26M) | (27.19M) | (23.28M) | (22.67M) | (22.50M) | (20.64M) | (15.60M) | (13.16M) | (10.27M) |
| Total Assets | 221.65M | 253.44M | 140.92M | 163.76M | 189.32M | 212.88M | 238.82M | 139.67M | 158.29M | 177.56M | 182.07M | 119.83M |
| Total Debt | 30.11M | 29.91M | 29.83M | 29.74M | 29.64M | 26.73M | 26.71M | 26.64M | 26.56M | 26.49M | 26.70M | 26.30M |
| Cash & Equiv | 38.79M | 33.18M | 16.28M | 17.44M | 19.56M | 15.13M | 21.43M | 23.86M | 16.79M | 26.59M | 27.69M | 22.75M |
| Book Value | 176.04M | 203.13M | 94.39M | 120.48M | 147.85M | 171.45M | 199.35M | 101.73M | 121.86M | 140.37M | 146.54M | 87.72M |
| Return on Equity | -0.21 | -0.16 | -0.31 | -0.25 | -0.18 | -0.17 | -0.12 | -0.22 | -0.17 | -0.11 | -0.11 | -0.13 |
SVRA News
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
Savara Announces New Employment Inducement Grant
Savara Announces Chief Financial and Administrative Officer Transition
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)